The polymorphism P187S in human NQO1 eliminates the enzymatic activity of NQO1 by greatly reducing its binding affinity to FAD, which is associated with an increased risk of various cancers, including prostate cancer, adult brain tumors, and colorectal adenoma.[47–49] Furthermore, it serves as an important prognostic factor for breast cancer.[50] In this study, a novel germline mutation, P115S, was identified in 6 patients (60%). Here, NQO1 is linked to prostate cancer.